

Press Release – Basel, Switzerland January 11th 2006

New Release Genedata Screener Improves Strategy for High Throughput Screening Analysis

Genedata announces the release of Genedata Screener® 4.0, an open and scalable solution for high throughput screening (HTS) analysis. The software now boasts a well documented public application programming interface (API) and advanced procedures for analyzing high content screening data.

"We've created a powerful and straightforward strategy for validating data quality and pinpointing the most promising lead compounds", says Dr. Michael Lindemann, Business Head Genedata Screener. The software handles high content screening data and consolidates Screener's strengths in compound potency measurement using dose-response curve fitting.

New features include an API to link Screener's database resources with the client's existing corporate information portals. The release has new sorting and filtering capabilities that have been specially developed for lead discovery and compound validation.

"Screener 4.0 addresses recent moves in HTS towards cellular systems, biomolecular aspects of ADMET, and functional genomics", explained Dr. Stephan Heyse, Project Head Genedata Screener. Genedata has honed its competencies in high content screening data analysis. It recently issued a joint statement with Evotec Technologies describing a high throughput solution for imaging screens. These features have been integrated into the 4.0 release.

Screener's open architecture facilitates tight IT integration without costly customization. Dr. Lindemann added, "Our technologies bring benefit to focused screening campaigns in specific therapeutic areas as well as large scale screening operations".

Contact

Genedata AG
Dr. Tobe Freeman
Manager Public Relations
Phone +41 61 697 8510
Fax +41 61 697 7244
tobe.freeman@genedata.com
www.genedata.com

Genedata specializes in computational solutions for life science research, drug discovery, and drug development. The Company combines a comprehensive, scientifically validated computational platform with expert scientific consulting services to provide tailor-made solutions for specific applications and multiple therapeutic areas. Founded in 1997 as a spin-off from Novartis, the Company is privately held and has grown to an interdisciplinary, international team of dedicated experts. Genedata is headquartered in Basel (Switzerland) with subsidiaries and branch offices in Munich (Germany), San Francisco (USA), and Boston (USA). The Company is also represented by Infocom Corporation (Japan), DigiGenomics (Taiwan), and Research Instruments (Singapore, Malaysia). For more information about Genedata, please visit: www.genedata.com.

Disclaimer

The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.